Dataset Information


The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation.

ABSTRACT: Oncogenic transcription factors such as the leukemic fusion protein RUNX1/ETO, which drives t(8;21) acute myeloid leukemia (AML), constitute cancer-specific but highly challenging therapeutic targets. We used epigenomic profiling data for an RNAi screen to interrogate the transcriptional network maintaining t(8;21) AML. This strategy identified Cyclin D2 (CCND2) as a crucial transmitter of RUNX1/ETO-driven leukemic propagation. RUNX1/ETO cooperates with AP-1 to drive CCND2 expression. Knockdown or pharmacological inhibition of CCND2 by an approved drug significantly impairs leukemic expansion of patient-derived AML cells and engraftment in immunodeficient murine hosts. Our data demonstrate that RUNX1/ETO maintains leukemia by promoting cell cycle progression and identifies G1 CCND-CDK complexes as promising therapeutic targets for treatment of RUNX1/ETO-driven AML.

SUBMITTER: Martinez-Soria N 

PROVIDER: S-EPMC6179967 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-04-12 | GSE117107 | GEO
2019-04-12 | GSE117105 | GEO
1000-01-01 | S-EPMC3419980 | BioStudies
1000-01-01 | S-EPMC3412349 | BioStudies
2017-01-01 | S-EPMC5522207 | BioStudies
2021-01-01 | S-EPMC7856722 | BioStudies
2014-01-01 | S-EPMC3987666 | BioStudies
2012-01-01 | S-EPMC3286215 | BioStudies
2020-01-01 | S-EPMC7262600 | BioStudies
2019-01-01 | S-EPMC6899442 | BioStudies